H. Wedemeyer

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

B. Sangro, Stephen L. Chan, Robin Kate Kelley et al. · Annals of Oncology · 2024 · 254 citations · Full text

Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals

Julia Dietz, S. Süsser, Johannes Vermehren et al. · Gastroenterology · 2017 · 147 citations

Viral Hepatitis, Direct-acting Antivirals, Antiviral Therapy +8

Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients

Svjetlana Lovric, Uta Erdbrüegger, P. Kumpers et al. · Nephrology Dialysis Transplantation · 2008 · 87 citations · Full text

O4 PROLONGED THERAPY OF HEPATITIS DELTA FOR 96 WEEKS WITH PEGYLATED-INTERFERON-α-2a PLUS TENOFOVIR OR PLACEBO DOES NOT PREVENT HDVRNA RELAPSE AFTER TREATMENT: THE HIDIT-2 STUDY

H. Wedemeyer, S. Ernst, Florin Alexandru Căruntu et al. · Journal of Hepatology · 2014 · 54 citations

Hidit-2 Study, Viral Hepatitis, Immunology +5

1419 A RANDOMIZED TRIAL COMPARING RIBAVIRIN DOSE REDUCTION VERSUS ERYTHROPOIETIN FOR ANEMIA MANAGEMENT IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC HEPATITIS C RECEIVING BOCEPREVIR PLUS PEGINTERFERON/RIBAVIRIN

F. Poordad, E.J. Lawitz, K. Rama Reddy et al. · Journal of Hepatology · 2012 · 43 citations · Full text

Hepatology, Viral Hepatitis, Hematology +5